Group 1 - The core viewpoint of the news highlights the recent trading performance and financial metrics of Haili Biological, indicating a slight increase in stock price and a net financing outflow on October 22 [1] - On October 22, Haili Biological's stock price rose by 0.28%, with a trading volume of 31.17 million yuan. The financing buy-in amount was 4.60 million yuan, while the financing repayment was 5.52 million yuan, resulting in a net financing outflow of 0.92 million yuan [1] - As of October 22, the total margin balance for Haili Biological was 219 million yuan, with the financing balance accounting for 4.79% of the circulating market value, which is below the 30th percentile level over the past year, indicating a low level of financing [1] Group 2 - As of June 30, Haili Biological had 31,500 shareholders, an increase of 0.14% from the previous period, while the average circulating shares per person decreased by 0.14% to 20,569 shares [2] - For the first half of 2025, Haili Biological reported an operating income of 110 million yuan, representing a year-on-year growth of 2.02%, and a net profit attributable to shareholders of 18.23 million yuan, which is a 20.56% increase year-on-year [2] - Haili Biological has distributed a total of 209 million yuan in dividends since its A-share listing, with 107 million yuan distributed over the past three years [3]